Christophe Pouchoy, Managing Director and Managing Director of Trecento Asset Management, co-manager of the Trecento Santé fund, answered questions from the Pharmaceutiques magazine about the recent acquisitions and some reconciliations of big pharma and major biotech companies.
« Because, before buying a company, the laboratories study the expected sales multiples over the coming years and the peak sales anticipated in the next three to five years. So, they’re focusing on the 2022-2023 horizon, the necessary deadline for the companies they want to buy back, to register their (…) »
Read the article by clicking here (available in French only)